Lidokain Aguettant (Lidocaine Hydrochloride)

Lidokain Aguettant is a local anesthetic that acts on peripheral nerves and cardiac tissue to produce temporary loss of sensation or modify electrical conduction.

• Minor surgical or diagnostic procedures: provides temporary loss of sensation to facilitate the procedure.
• Infiltration anesthesia: enables localized numbness for tissue infiltration during minor surgeries.
• Intravenous antiarrhythmic therapy: used under monitoring to manage certain cardiac arrhythmias.

• Lidocaine hydrochloride reversibly blocks voltage‑gated sodium channels on neuronal and cardiac cell membranes, preventing the initiation and propagation of action potentials. This inhibition reduces nerve impulse transmission and stabilizes cardiac membranes, producing local anesthesia and antiarrhythmic effects without affecting other ion channels at therapeutic concentrations.

Adverse reactions may occur following administration of Lidokain Aguettant.

Common Side Effects

• Transient burning or stinging at the injection site
• Mild dizziness or light‑headedness
• Nausea or metallic taste
• Localized swelling or erythema

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis)
• Cardiac conduction abnormalities such as bradycardia or heart block
• Methemoglobinemia
• Central nervous system toxicity, including seizures or loss of consciousness

Before using Lidokain Aguettant, consider the following safety measures.

• Allergy assessment: verify no known hypersensitivity to amide‑type local anesthetics.
• Cardiovascular status: avoid in patients with severe heart block or conduction disorders.
• Dose limits: adhere to recommended maximum dose to prevent systemic toxicity.
• Concurrent CNS depressants: monitor for enhanced sedation when combined with other depressants.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk (category unknown).
• Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidokain Aguettant may interact with other medicines; review the following categories.

Major Interactions (Avoid)

• Class I antiarrhythmic agents (e.g., quinidine, procainamide): additive cardiotoxicity.
• Beta‑blockers: increased risk of bradycardia and hypotension.
• General anesthetics (e.g., propofol, volatile agents): potentiation of CNS depression.
• Monoamine oxidase inhibitors: enhanced local anesthetic toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding at injection sites.
• CYP3A4 inhibitors (e.g., erythromycin): can modestly raise plasma lidocaine levels.
• Diuretics: may alter electrolyte balance influencing cardiac effects.